DK1409016T4 - Antistoffer mod OPGL - Google Patents

Antistoffer mod OPGL Download PDF

Info

Publication number
DK1409016T4
DK1409016T4 DK02749660.3T DK02749660T DK1409016T4 DK 1409016 T4 DK1409016 T4 DK 1409016T4 DK 02749660 T DK02749660 T DK 02749660T DK 1409016 T4 DK1409016 T4 DK 1409016T4
Authority
DK
Denmark
Prior art keywords
opgl
antibodies
Prior art date
Application number
DK02749660.3T
Other languages
Danish (da)
English (en)
Other versions
DK1409016T3 (da
Inventor
Francis H Martin
Jose R Corvalan
Geoffrey C Davis
William J Boyle
Original Assignee
Amgen Inc
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1409016(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Amgen Fremont Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1409016T3 publication Critical patent/DK1409016T3/da
Publication of DK1409016T4 publication Critical patent/DK1409016T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
DK02749660.3T 2001-06-26 2002-06-25 Antistoffer mod OPGL DK1409016T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30117201P 2001-06-26 2001-06-26
PCT/US2002/020181 WO2003002713A2 (en) 2001-06-26 2002-06-25 Antibodies to opgl

Publications (2)

Publication Number Publication Date
DK1409016T3 DK1409016T3 (da) 2010-06-21
DK1409016T4 true DK1409016T4 (da) 2020-09-14

Family

ID=23162250

Family Applications (4)

Application Number Title Priority Date Filing Date
DK02749660.3T DK1409016T4 (da) 2001-06-26 2002-06-25 Antistoffer mod OPGL
DK10181323.6T DK2270052T3 (en) 2001-06-26 2002-06-25 Antibodies to OPGL
DK09156995.4T DK2087908T3 (en) 2001-06-26 2002-06-25 ANTIBODIES AGAINST OPGL
DK10185344.8T DK2295081T3 (en) 2001-06-26 2002-06-25 Antibodies to OPGL

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK10181323.6T DK2270052T3 (en) 2001-06-26 2002-06-25 Antibodies to OPGL
DK09156995.4T DK2087908T3 (en) 2001-06-26 2002-06-25 ANTIBODIES AGAINST OPGL
DK10185344.8T DK2295081T3 (en) 2001-06-26 2002-06-25 Antibodies to OPGL

Country Status (33)

Country Link
US (8) US7364736B2 (https=)
EP (5) EP2295081B1 (https=)
JP (13) JP4212470B2 (https=)
KR (2) KR101038585B1 (https=)
CN (2) CN103232539B (https=)
AR (1) AR034637A1 (https=)
AT (1) ATE464068T1 (https=)
AU (2) AU2002320157C1 (https=)
BR (1) BRPI0210579B8 (https=)
CA (1) CA2451955C (https=)
CY (5) CY1110196T1 (https=)
DE (2) DE60235989D1 (https=)
DK (4) DK1409016T4 (https=)
EA (1) EA021242B9 (https=)
ES (5) ES2675735T3 (https=)
FR (1) FR10C0050I2 (https=)
IL (3) IL159512A0 (https=)
LU (1) LU91757I2 (https=)
ME (2) MEP32608A (https=)
MX (1) MXPA04000134A (https=)
MY (1) MY143582A (https=)
NO (5) NO345566B1 (https=)
NZ (4) NZ616594A (https=)
PH (2) PH12012502439A1 (https=)
PL (1) PL222211B1 (https=)
PT (4) PT2270052T (https=)
RS (1) RS54274B1 (https=)
SG (3) SG10201603108QA (https=)
TR (3) TR201809678T4 (https=)
TW (2) TWI276443B (https=)
WO (1) WO2003002713A2 (https=)
YU (1) YU103003A (https=)
ZA (1) ZA200400521B (https=)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ES2284203T5 (es) * 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US8113839B2 (en) 2000-07-21 2012-02-14 Sony Corporation Information processing apparatus, information processing method, information processing system, and storage medium
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
EP2295081B1 (en) * 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
ATE458006T1 (de) * 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
DK1689777T3 (da) * 2003-11-05 2007-06-11 Ares Trading Sa Fremgangsmåde til oprensning af il18-bindende protein
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
US20060115901A1 (en) * 2004-10-22 2006-06-01 Bahram Valamehr Method and media for single cell serum-free culture of CHO cells
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP1869067A1 (en) * 2005-04-11 2007-12-26 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
AU2015242973C1 (en) * 2005-06-14 2018-07-05 Amgen Inc. Self-buffering protein formulations
BRPI0611901A2 (pt) * 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
WO2007016562A2 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) † 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
ES2375087T3 (es) 2006-04-28 2012-02-24 Kyoritsu Seiyaku Corporation Célula felina capaz de cultivarse sin proteína de origen animal, y procedimiento para producir un virus y procedimiento para producir una vacuna usando el mismo.
SI2061803T2 (sl) 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
ES3006441T3 (en) 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
BRPI0818437B8 (pt) * 2007-10-11 2021-05-25 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR101594046B1 (ko) 2008-01-09 2016-02-15 첼카 게엠베하 개선된 배양 배지 첨가제 및 이를 이용한 방법
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
TW201019959A (en) * 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
WO2010097386A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
MX343049B (es) 2009-04-09 2016-10-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
WO2011050333A1 (en) 2009-10-23 2011-04-28 Amgen Inc. Vial adapter and system
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
SG186094A1 (en) 2010-06-07 2013-01-30 Amgen Inc Drug delivery device
JP5699030B2 (ja) * 2010-07-05 2015-04-08 Ａｘｉｓ株式会社 エタネルセプトを含む線維筋痛症の治療剤
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
EP3517630B1 (en) 2010-10-06 2022-01-19 Institució Catalana de Recerca i Estudis Avançats Method for the diagnosis, prognosis and treatment of breast cancer metastasis
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
PL3045187T3 (pl) 2011-10-14 2019-09-30 Amgen Inc. Wstrzykiwacz i sposób montażu
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
JP6284181B2 (ja) * 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状ｒｎａ及びタンパク質の製造方法
MX2014011828A (es) 2012-03-30 2014-12-10 Daiichi Sankyo Co Ltd Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013181575A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR101872965B1 (ko) 2012-10-12 2018-06-29 인바이오모션 에스.엘. Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
ES2860954T3 (es) 2012-11-21 2021-10-05 Amgen Inc Dispositivo de administración de fármacos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
ES2802878T3 (es) 2013-01-25 2021-01-21 Baylor College Medicine Un sistema de administración y expresión de terapia génica adenoviral dependiente de linfocitos T colaboradores
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
US10646664B2 (en) 2013-03-15 2020-05-12 Amgen Inc. Body contour adaptable autoinjector device
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
JP6577873B2 (ja) 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
EP3030249B1 (en) 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US20160207988A1 (en) * 2013-09-24 2016-07-21 The Board Of Regents Of The University Of Texas System A novel hormone that promotes bone resorption and uses thereof
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
TR201907389T4 (tr) 2013-10-09 2019-06-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
PL3116891T3 (pl) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
CN111840696B (zh) 2014-06-03 2022-12-20 安姆根有限公司 可控制药物递送系统和使用方法
AU2015269365A1 (en) * 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
EP3206739B1 (en) 2014-10-14 2021-12-01 Amgen Inc. Drug injection device with visual and audio indicators
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び／または戻りが真空によって支援された薬物送達装置
US10328123B2 (en) 2015-02-25 2019-06-25 Saint Louis University Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis
US10111928B1 (en) * 2015-02-25 2018-10-30 Saint Louis University Pulsed introduction of low-dose RANKL as a therapy for osteogenesis imperfecta
US10745461B2 (en) 2015-02-25 2020-08-18 Saint Louis University Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2889902T3 (es) 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
HU231463B1 (hu) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
DK3334747T5 (da) 2015-08-13 2024-10-07 Amgen Inc Ladet dybdefiltrering af antigenbindende proteiner
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
BR112018068103A2 (pt) 2016-03-08 2019-01-15 Janssen Biotech Inc anticorpos gitr, métodos e usos
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
CN110049773A (zh) 2016-07-14 2019-07-23 供石公司 TGFβ抗体、方法和用途
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
EP3592403B1 (en) 2017-03-06 2025-08-20 Amgen Inc. Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
ES3023742T3 (en) 2017-03-28 2025-06-03 Amgen Inc Plunger rod and syringe assembly system
SI4190355T1 (sl) 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
ES2971450T3 (es) 2017-10-06 2024-06-05 Amgen Inc Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en) 2017-11-03 2024-12-01 Amgen Inc Systems and approaches for sterilizing a drug delivery device
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
HU231498B1 (hu) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
JP2022530241A (ja) 2019-04-30 2022-06-28 インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
CN113621060B (zh) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 一种opg抗体对及其应用
JP2024523779A (ja) 2021-05-21 2024-07-02 アムジェン インコーポレイテッド 薬物容器用の充填レシピを最適化する方法
AU2023347288A1 (en) 2022-09-23 2025-03-13 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
CN120076828A (zh) * 2022-11-16 2025-05-30 苏州盛迪亚生物医药有限公司 一种含抗rankl-ngf双特异性抗体的药物组合物
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0192658A4 (en) 1984-07-30 1987-07-13 Salk Inst For Biological Studi RETROVIRAL GENE TRANSFER VECTORS.
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4760130A (en) 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
US5900400A (en) 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
JPS6291197A (ja) 1985-10-17 1987-04-25 Dainippon Pharmaceut Co Ltd 抗ヒトインタ−ロイキン１抗体，その製法及びその使用法
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5359032A (en) 1987-08-26 1994-10-25 Biogen Inc. Interkeukin-1 inhibitor
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
HU215434B (hu) 1988-05-27 1999-04-28 Synergen Inc. Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
EP0364778B1 (en) 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antibody against interleukin-1beta
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
IL107267A (en) 1993-10-12 2009-07-20 Yeda Res & Dev Ligand to a member of the tnf/ngf receptor family
AU636608B2 (en) 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
EP0502956B1 (en) 1989-11-29 1997-04-23 Amgen Boulder Inc. Production of recombinant human interleukin-1 inhibitor
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
AU649245B2 (en) 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
WO1991017184A1 (en) 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
AU655766B2 (en) 1990-05-01 1995-01-12 Chiron Corporation Interleukin-1 antagonist and uses thereof
US5872095A (en) 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
DK0542795T5 (da) 1990-08-03 1998-09-07 Smithkline Beecham Corp TNF-inhibitorer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5840496A (en) 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5858355A (en) 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
NZ314630A (en) 1991-01-17 2000-11-24 Harvard College Use of trans-splicing ribozymes for genetic modification and cell ablation in a host cell
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
ES2038546B1 (es) 1991-11-08 1994-02-16 Andromaco Lab Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
EP0584347B1 (en) 1992-03-04 2003-01-15 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
ATE242322T1 (de) 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
ATE188610T1 (de) 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
DE4219626A1 (de) 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
JPH0630788A (ja) 1992-07-16 1994-02-08 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−１に対する組換え抗体
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
ATE257389T1 (de) 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
JPH06111399A (ja) 1992-09-30 1994-04-22 Sony Corp 光磁気記録媒体及びその製造方法
WO1994007498A1 (fr) 1992-10-07 1994-04-14 Sumitomo Pharmaceuticals Company, Limited Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5891438A (en) * 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
US5866576A (en) 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
ES2124801T3 (es) 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
CA2157782A1 (en) 1993-03-08 1994-09-15 Joseph C. Glorioso Gene transfer for treating a connective tissue of a mammalian host
EP0689449B1 (fr) 1993-03-19 2002-10-30 Vacsyn S.A. Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US5843905A (en) 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
FR2706772A1 (en) 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JP3775685B2 (ja) 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
CA2175458C (en) 1993-11-29 1999-03-02 Boyd L. Harrison Novel benzenesulfonylimine derivatives as inhibitors of il-1 action
CA2138305A1 (en) 1993-12-28 1995-06-29 Naohito Ohashi Tumor necrosis factor production inhibitors
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
JPH09511496A (ja) 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
DE69503769T2 (de) 1994-03-09 1998-12-03 Pfizer Inc., New York, N.Y. Isoxazoline verbindung zur hemmung tnf-freigabe
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5817822A (en) 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
IL114417A0 (en) 1994-07-07 1995-10-31 Res Dev Foundation Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US5641747A (en) 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
IT1269989B (it) 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
CZ288436B6 (en) 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5852173A (en) 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
WO1996019990A1 (en) 1994-12-23 1996-07-04 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
ZA9510826B (en) 1994-12-23 1996-06-20 Smithkline Beecham Corp 3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5886010A (en) 1995-01-09 1999-03-23 Otsuka Pharmaceutical Company, Limited TNF-αinhibitor
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
HUP9800049A3 (en) 1995-02-23 1999-01-28 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
JPH11507205A (ja) 1995-04-27 1999-06-29 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体
EP0824543A1 (en) 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
AR004471A1 (es) 1995-05-31 1998-12-16 Smithkline Beecham Corp Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
US5817476A (en) 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US5830742A (en) 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
EP0859779A4 (en) 1995-08-31 2000-04-12 Smithkline Beecham Corp INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
AU7169296A (en) 1995-09-27 1997-04-17 Board Of Trustees Of The Leland Stanford Junior University Methods for determining t-cell profiles of immunocompromised subjects
WO1997012902A1 (en) 1995-10-05 1997-04-10 Darwin Discovery Limited Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation
DE19540475A1 (de) 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
CA2237524A1 (en) 1995-11-14 1997-05-22 Du Pont Pharmaceuticals Company Novel macrocyclic compounds as metalloprotease inhibitors
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CO4750805A1 (es) * 1995-12-13 1999-03-31 Sumitomo Chemical Co Compuesto para champu
US5869315A (en) 1995-12-18 1999-02-09 Basf Aktiengesellschaft Modified interleukin-1β converting enzyme with increased stability
US5990119A (en) 1995-12-21 1999-11-23 Smithkline Beecham Corporation 1,4,4-(trisubstituted)cyclohexane monomers and related compounds
US5891883A (en) 1995-12-21 1999-04-06 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US5869677A (en) 1995-12-21 1999-02-09 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
EP0870028A1 (en) 1995-12-29 1998-10-14 Incyte Pharmaceuticals, Inc. Nucleic acids encoding interferon gamma inducing factor-2
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
SK288144B6 (sk) 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US5994351A (en) 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US5981220A (en) 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607249D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
GB9609795D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
AUPO048296A0 (en) 1996-06-14 1996-07-11 Fujisawa Pharmaceutical Co., Ltd. New compound and its preparation
EP0816499A3 (en) 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
EP0818439B1 (en) 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Imide derivatives
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH10130149A (ja) 1996-07-12 1998-05-19 Sankyo Co Ltd Ｔｎｆ産生抑制剤
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US5877222A (en) 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US6069132A (en) 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
ES2217428T3 (es) 1996-09-25 2004-11-01 Ss Pharmaceutical Co., Ltd. Derivados de vinilpiridina sustituidos y medicamentos que los contienen.
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB9621859D0 (en) 1996-10-21 1996-12-11 Xenova Ltd Cytokine production inhibitors
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
JPH10147531A (ja) 1996-11-19 1998-06-02 Otsuka Pharmaceut Co Ltd ＴＮＦ−α産生抑制剤
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5955480A (en) 1996-11-20 1999-09-21 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5834435A (en) 1996-11-27 1998-11-10 Slesarev; Vladimir I. Inhibition of TNF-α pleiotropic and cytotoxic effects
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
PT1114864E (pt) 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
DE19652227A1 (de) 1996-12-16 1998-06-18 Bosch Gmbh Robert Verfahren und Vorrichtung zum Zuordnen einer Fernbedienung zu einer Basisstation
JPH10231285A (ja) 1996-12-17 1998-09-02 Ishihara Sangyo Kaisha Ltd フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物
WO1998028423A2 (en) 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
PT853083E (pt) 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
ZA9818B (en) 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5952320A (en) 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6054559A (en) 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
AU723895B2 (en) 1997-01-29 2000-09-07 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
ATE287885T1 (de) 1997-03-04 2005-02-15 Pharmacia Corp Hydroxamsäure-sulfonamid-derivate mit amidiertem aromatischen ring
NZ337326A (en) 1997-03-04 2001-05-25 Monsanto Co Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
JPH10259140A (ja) 1997-03-18 1998-09-29 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生抑制剤
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
WO1998042325A2 (en) 1997-03-21 1998-10-01 Cistron Biotechnology, Inc. INHIBITION OF THE CLEAVAGE OF PRECURSOR IL-1$g(b)
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
AU6843498A (en) 1997-03-28 1998-10-22 Zeneca Limited Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
US6251913B1 (en) 1997-03-28 2001-06-26 Zeneca Limited Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
AU738037B2 (en) 1997-04-04 2001-09-06 Pfizer Products Inc. Nicotinamide derivatives
EP0979099B1 (en) 1997-04-10 2005-06-15 Agennix, Inc. Use of lactoferin in the treatment of allergen induced disorders
CA2286290A1 (en) 1997-04-15 1998-10-22 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
ES2284203T5 (es) † 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
IL132736A0 (en) 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
JPH111481A (ja) 1997-06-10 1999-01-06 Sumitomo Pharmaceut Co Ltd ピペリジニルフタラジン誘導体
KR19990001101A (ko) 1997-06-12 1999-01-15 손경식 캐테콜 아미노산 유도체, 이의 제조방법 및 그를 함유한 약제 조성물
DE69835518T2 (de) 1997-06-12 2007-08-09 Aventis Pharma Ltd., West Malling Imidazolyl-cyclische acetale
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
JPH119269A (ja) 1997-06-19 1999-01-19 Kaken Pharmaceut Co Ltd 破骨細胞系細胞
GB9713733D0 (en) 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Poly-branched polycarboxamido compounds
GB9713732D0 (en) 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Substituted triazinic compounds
US6235787B1 (en) 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
AU8280798A (en) 1997-07-03 1999-01-25 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US5843721A (en) 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
WO1999002510A1 (en) 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
DE19731521A1 (de) 1997-07-23 1999-01-28 Byk Gulden Lomberg Chem Fab Budipin bei der Behandlung entzündlicher Erkrankungen des Nervensystems
FR2766822B1 (fr) 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR016551A1 (es) 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
HUP0003761A3 (en) 1997-07-31 2001-04-28 Celgene Corp Warren Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
EP1003751A1 (en) 1997-08-04 2000-05-31 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
WO1999006426A1 (en) 1997-08-04 1999-02-11 Millennium Biotherapeutics, Inc. Novel molecules of the tango-77 related protein family and uses thereof
CA2268190A1 (en) 1997-08-06 1999-02-18 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
ES2176913T3 (es) 1997-08-08 2002-12-01 Pfizer Prod Inc Derivados de acidos arilsulfonilaminohidroxamicos.
WO1999007679A1 (en) 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
AU8747998A (en) 1997-08-21 1999-03-16 Takeda Chemical Industries Ltd. Anti-inflammatory agent
JPH11139994A (ja) 1997-10-31 1999-05-25 Kureha Chem Ind Co Ltd 抗腫瘍剤
JP2001521906A (ja) 1997-11-03 2001-11-13 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 血管新生を阻害し、癌を処置するための方法及び組成物
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JP2002509143A (ja) 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオエーテルフランニトロン化合物
PT1049703E (pt) 1998-01-20 2003-06-30 Warner Lambert Co Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
EP1047781B1 (en) 1998-01-23 2004-07-28 Immunex Corporation Il-18 receptors
CA2318030C (en) 1998-01-23 2009-02-17 Immunex Corporation Acpl dna and polypeptides
EP1051407A1 (en) 1998-01-27 2000-11-15 American Cyanamid Company 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
WO1999037818A1 (en) 1998-01-27 1999-07-29 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
WO1999046248A1 (en) 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
KR20010041905A (ko) 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
TWI243828B (en) 1998-03-19 2005-11-21 Vertex Pharma Inhibitors of caspases
IL126024A0 (en) 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
CN1181817C (zh) 1998-03-20 2004-12-29 第一三得利制药株式会社 以苯基甲苯醌为有效成分的NF-kB抑制剂
JPH11266872A (ja) 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
CN1305846C (zh) 1998-03-26 2007-03-21 参天制药株式会社 脲衍生物
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
KR100537558B1 (ko) 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
HUP0103578A3 (en) * 1998-09-15 2005-11-28 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CZ302706B6 (cs) * 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
AU773954B2 (en) 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
WO2000047740A2 (en) 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
WO2001044472A1 (en) 1999-12-16 2001-06-21 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
EP1254227A2 (en) 2000-02-11 2002-11-06 Amgen Inc. Fusion receptor from tnf family
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
SI1257648T2 (sl) † 2000-02-23 2016-11-30 Amgen Inc. Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
US7102050B1 (en) 2000-05-04 2006-09-05 Exxonmobil Chemical Patents Inc. Multiple riser reactor
HK1054316A1 (zh) * 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
US7405734B2 (en) * 2000-07-18 2008-07-29 Silicon Graphics, Inc. Method and system for presenting three-dimensional computer graphics images using multiple graphics processing units
DE10039710B4 (de) 2000-08-14 2017-06-22 United Monolithic Semiconductors Gmbh Verfahren zur Herstellung passiver Bauelemente auf einem Halbleitersubstrat
WO2002016551A2 (en) * 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
CA2447518A1 (en) 2001-05-17 2002-11-21 Immunex Corporation Therapeutic use of rank antagonists
MXPA03011270A (es) 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
EP2295081B1 (en) * 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
US7718776B2 (en) † 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP3492100A1 (en) 2019-06-05
SG10201603108QA (en) 2016-05-30
CY1121151T1 (el) 2020-05-29
WO2003002713A3 (en) 2003-08-14
JP2009022280A (ja) 2009-02-05
JP2015078205A (ja) 2015-04-23
PH12012502440A1 (en) 2013-06-17
US8409578B2 (en) 2013-04-02
ES2706902T3 (es) 2019-04-01
DK2087908T3 (en) 2018-07-23
SG173211A1 (en) 2011-08-29
NO20200535A1 (no) 2004-03-10
NZ530765A (en) 2006-11-30
KR101038585B1 (ko) 2011-06-03
AU2008261137C1 (en) 2023-08-31
ES2907826T3 (es) 2022-04-26
JP4212470B2 (ja) 2009-01-21
PT1409016E (pt) 2010-06-11
US20170183417A1 (en) 2017-06-29
PL371915A1 (en) 2005-07-11
JP2012153701A (ja) 2012-08-16
TW200630107A (en) 2006-09-01
ATE464068T1 (de) 2010-04-15
AU2008261137A1 (en) 2009-01-15
NO2019039I1 (no) 2019-11-05
CA2451955A1 (en) 2003-01-09
JP2005506963A (ja) 2005-03-10
ME00232B (me) 2011-02-10
CN103232539A (zh) 2013-08-07
NO20190456A1 (no) 2004-03-10
DK2270052T3 (en) 2018-07-02
LU91757I2 (fr) 2011-01-24
KR20040023630A (ko) 2004-03-18
NO344842B1 (no) 2020-05-25
US20200131271A1 (en) 2020-04-30
ES2342820T5 (es) 2021-04-14
MEP32608A (hr) 2011-02-10
CY2010016I1 (el) 2012-01-25
JP4358282B2 (ja) 2009-11-04
EA021242B1 (ru) 2015-05-29
CN103232539B (zh) 2015-06-03
JP2019214563A (ja) 2019-12-19
EA200400063A1 (ru) 2005-02-24
PH12012502439A1 (en) 2013-06-17
TR201809008T4 (tr) 2018-07-23
NZ616594A (en) 2015-06-26
RS20120347A2 (sr) 2013-04-30
DK1409016T3 (da) 2010-06-21
CY1120656T1 (el) 2019-12-11
EP2270052A2 (en) 2011-01-05
BR0210579A (pt) 2005-05-10
PL222211B1 (pl) 2016-07-29
AR034637A1 (es) 2004-03-03
ES2675735T3 (es) 2018-07-12
EP1409016B1 (en) 2010-04-14
DE60235989D1 (de) 2010-05-27
TR201900581T4 (tr) 2019-02-21
NO343687B1 (no) 2019-05-06
CY2010016I2 (el) 2012-01-25
MY143582A (en) 2011-05-31
RS20120347A3 (en) 2013-10-31
JP2020073518A (ja) 2020-05-14
JP2016216464A (ja) 2016-12-22
YU103003A (sh) 2006-05-25
NO2019048I1 (no) 2019-12-20
RS54274B1 (sr) 2016-02-29
TWI276443B (en) 2007-03-21
HK1187932A1 (zh) 2014-04-17
IL159512A (en) 2014-12-31
TR201809678T4 (tr) 2018-07-23
US7364736B2 (en) 2008-04-29
IL159512A0 (en) 2004-06-01
JP2015057408A (ja) 2015-03-26
PT2295081T (pt) 2019-02-01
CY1120658T1 (el) 2019-12-11
US8058418B2 (en) 2011-11-15
PT2270052T (pt) 2018-07-04
MXPA04000134A (es) 2005-06-06
ZA200400521B (en) 2005-07-27
US20120087923A1 (en) 2012-04-12
JP2009273466A (ja) 2009-11-26
EP1409016B2 (en) 2020-07-15
EP1409016A4 (en) 2005-11-09
JP2018154614A (ja) 2018-10-04
EP2270052B8 (en) 2018-05-02
NZ547695A (en) 2008-09-26
US20200354464A1 (en) 2020-11-12
BRPI0210579B8 (pt) 2021-05-25
JP4927910B2 (ja) 2012-05-09
JP2022000424A (ja) 2022-01-04
LU91757I9 (https=) 2019-01-03
IL235116A0 (en) 2014-11-30
AU2002320157C1 (en) 2023-09-21
EP2270052B1 (en) 2018-03-28
ES2342820T3 (es) 2010-07-15
JP2012229236A (ja) 2012-11-22
EP2087908B1 (en) 2018-05-30
JP5576903B2 (ja) 2014-08-20
EP2270052A3 (en) 2011-03-02
WO2003002713A2 (en) 2003-01-09
DE122010000047I1 (de) 2011-05-05
EA021242B9 (ru) 2015-11-30
SG2011076551A (en) 2015-08-28
BRPI0210579B1 (pt) 2019-05-14
EP1409016A2 (en) 2004-04-21
EP2295081A1 (en) 2011-03-16
JP2012140430A (ja) 2012-07-26
US20140134157A1 (en) 2014-05-15
EP2087908A1 (en) 2009-08-12
AU2002320157B2 (en) 2008-10-16
US20150266952A1 (en) 2015-09-24
NO345566B1 (no) 2021-04-19
JP5065529B2 (ja) 2012-11-07
ES2674888T3 (es) 2018-07-04
EP2295081B1 (en) 2018-10-31
NZ581637A (en) 2012-05-25
US20040033535A1 (en) 2004-02-19
NO20041018L (no) 2004-03-10
FR10C0050I1 (https=) 2011-01-14
US20090274688A1 (en) 2009-11-05
EP3492100B1 (en) 2021-12-08
EP1409016B9 (en) 2020-10-28
CY1110196T1 (el) 2012-01-25
KR20100041797A (ko) 2010-04-22
TWI326285B (en) 2010-06-21
AU2008261137B2 (en) 2012-10-04
CN1547486A (zh) 2004-11-17
CA2451955C (en) 2015-09-29
DK2295081T3 (en) 2019-02-18
PT2087908T (pt) 2018-07-16
FR10C0050I2 (fr) 2011-12-30

Similar Documents

Publication Publication Date Title
DK1409016T3 (da) Antistoffer mod OPGL
DK1476185T3 (da) Antistoffer mod CD40
NO20034925D0 (no) Cykliske N-aroylaminer
DK1313769T3 (da) Antistoffer mod humant IL-1beta
EE200300509A (et) Antikehad VLA-1 vastu
DE60236964D1 (de) Füllvorrichtung
FI20000854A0 (fi) Adsorbenttikatalyytti
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE60234481D1 (de) Verschachtelungsverfahren
DE50208629D1 (de) Pedal
DE60234699D1 (de) Hydrosilylierungsverfahren
DE50207829D1 (de) Pedal
DE10111783B4 (de) Einspritzdüse
SE0401180L (sv) Adsorber
ATA17102002A (de) Distanzhalter
DE60229395D1 (de) Altung
DE50204124D1 (de) Pumpe-düse-einheit
DE50212042D1 (de) Pedal
DE50211331D1 (de) Pedal
DE50211332D1 (de) Pedal
ATE303835T1 (de) Spritze
ATE296652T1 (de) Spritze
SE0102576D0 (sv) Tefat
PT9700T (pt) Divisoria extensivel
FI5542U1 (fi) Jakotukki